Research
Energy balance
SGLT2 inhibitors reduce body weight and blood pressure, contributing to their overall benefit in CRM syndrome.
SGLT2 inhibitors typically lead to a modest weight loss of 1.5-3 kg over 1-2 years, which is a beneficial side effect for managing metabolic syndrome.
GoodSupportsHIGH confidence
Meta-analyses indicate that SGLT2is lead to a dose-dependent body weight reduction of about 1.5 to 2 kg relative to placebo
Why this rating
Supported by meta-analyses of multiple trials.
Source
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Konstantinos Grigoriou et al. · Medicina · 2025
DOI 10.3390/medicina61111903
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with cardio-renal-metabolic syndrome, regardless of diabetes status.Strong
- SGLT2 inhibitors improve mitochondrial function and reduce oxidative stress, contributing to their cardioprotective and renoprotective effects.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →